Dimerix Limited (ASX:DXB)
Australia · Delayed Price · Currency is AUD
0.4550
+0.0150 (3.41%)
Feb 26, 2026, 4:10 PM AEST
Revenue by Segment
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | Jun '18 Jun 30, 2018 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 |
|---|
Development of Occupational Drug Testing Devices and New Therapeutic Agents | 5.59M | 407.47K | - | - | - | | | | | |
Development of Occupational Drug Testing Devices and New Therapeutic Agents Growth | 1271.12% | - | - | - | - | | | | | |
| - | - | 36.79K | 6.46M | 4.44M | | | | | |
| - | - | -99.43% | 45.58% | 89.65% | | | | | |
| 5.59M | 407.47K | 36.79K | 6.46M | 4.44M | | | | | |
| 1271.12% | 1007.64% | -99.43% | 45.58% | 89.65% | | | | | |
Revenue by Geography
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | Jun '19 Jun 30, 2019 | Jun '18 Jun 30, 2018 | Jun '17 Jun 30, 2017 | Jun '16 Jun 30, 2016 |
|---|
| 5.59M | 407.47K | 36.79K | 6.46M | 4.44M | | | | | |
| 1271.12% | 1007.64% | -99.43% | 45.58% | 89.65% | | | | | |
| 5.59M | 407.47K | 36.79K | 6.46M | 4.44M | | | | | |
| 1271.12% | 1007.64% | -99.43% | 45.58% | 89.65% | | | | | |
Source: S&P Global Market Intelligence.
